Last reviewed · How we verify
NCT00003372
Topotecan in Treating Patients With Recurrent Brain Tumors
Phase 2 trial testing topotecan hydrochloride in Brain and Central Nervous System Tumors in 17 participants. Completed in 21 December 2009.
5 October 2000
Quick facts
| Lead sponsor | NCIC Clinical Trials Group |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 17 |
| Start date | 8 December 1997 |
| Primary completion | 5 October 2000 |
| Estimated completion | 21 December 2009 |
| Sites | 11 locations across Canada |
Drugs / interventions tested
- topotecan hydrochloride — full drug profile →
Conditions studied
- Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →
Sponsor
NCIC Clinical Trials Group
Who can join
Adults 18 to 120, any sex, with Brain and Central Nervous System Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent brain tumor.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00003372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of topotecan hydrochloride
Trials testing the same drug.
- NCT00499616 — Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma · Phase 3 · completed
- NCT00638898 — Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Re · Phase 1 · completed
- NCT00025272 — Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
- NCT00028743 — Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · Phase 3 · completed
- NCT00002950 — Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer · Phase 1, PHASE2 · completed
Other recruiting trials for Brain and Central Nervous System Tumors
Currently open trials in the same condition.
- NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting
Other NCIC Clinical Trials Group trials
Trials by the same sponsor.
- NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
- NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
- NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
- NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
- NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00003372 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
- Last refreshed: 8 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00003372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing